MedPath

MYLAN-ABACAVIR/LAMIVUDINE

MYLAN-ABACAVIR/LAMIVUDINE

Approved
DIN Number

02450682

Drug Class

Human

Market Date

Mar 29, 2016

Company
HC

Mylan Pharmaceuticals ULC

Product Information

Detailed information about this Health Canada approved drug product, including dosage form, route of administration, and regulatory classification.

Product Details

Health Canada regulatory and product classification information

Regulatory Identifiers
DIN Number02450682
AIG Number0251241001
Classification & Schedule
C
Drug Class
Human
S
Schedule
Prescription
A
ATC Code
J05AR02 LAMIVUDINE AND ABACAVIR
Product Specifications
Dosage FormTablet
Route of AdministrationOral
AHFS Classification08:18.08.20
Health Canada Classification

ACTIVE INGREDIENTS (2)

ABACAVIR (ABACAVIR SULFATE)Active
Strength: 600 MG
Monograph: ABACAVIR (ABACAVIR SULFATE)
LAMIVUDINEActive
Strength: 300 MG
Monograph: LAMIVUDINE

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.